

## BOB ICB and Frimley ICB Priorities Committee Clinical Commissioning Policy Statement

Policy Number/ Name	BOBFPC41 Implementation of NICE Interventional Procedures Guidance (IPGs), Medical Technologies Guidance (MTGs) and Diagnostic Technologies Guidance (DTGs)
Date of BOB ICB Adoption	March 2024

NHS ICBs have no statutory duty to fund the use of the procedures or technologies assessed under the National Institute for Health and Clinical Excellence (NICE) Interventional Procedures Guidance (IPG), Medical Technologies Guidance (MTG) and Diagnostic Technologies Guidance (DTG) programmes.

Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee has considered these types of NICE guidance, and agreed that the use of any procedure or technology assessed by NICE under their IPG, MTG and DTG programmes are **not normally funded** unless:

1. the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'  
**OR**  
the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'  
**OR**  
the NICE DTG makes a recommendation as an option for use  
**AND**
2. funding has been agreed by commissioners through either of the funding routes detailed below.

To obtain funding, in advance of the use of an interventional procedure, medical or diagnostic technology:

- the provider must submit a business case to the ICB for approval  
**OR**
- The ICB agrees to commission the procedure or technology following consideration of an evidence review and positive recommendation by the Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee

Regardless of equivalent cost, the ICB will not commission the use of interventions or technologies that are less effective or pose a greater risk to patients than standard interventions.

Trusts wishing to undertake research associated with the use of new technologies and interventions, including IPG, MTG or DTG technologies, must apply for research funds in the usual way.

A NICE IPG recommendation for use with standard arrangements means that there is enough evidence to show that the procedure works well enough and is safe enough for doctors to consider it as an option for their patients, providing that they follow their hospital's existing policies around getting permission to perform operations and monitoring the results afterwards. The recommendation does not mean that all patients who have the condition or symptom in question "should" or "must" be offered the procedure - this is decided at a local NHS level. An IPG does not consider the cost or cost-effectiveness of a procedure.

A NICE MTG reviews the clinical and cost impact evidence for a technology compared with currently available technologies. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

A NICE DTG focuses on the evaluation of an innovative medical diagnostic technology in order to ensure that the NHS is able to adopt clinically and cost-effective technologies rapidly and consistently. Positive recommendations are clearly stated as options only.

This policy is in alignment with NICE Guidance for [Interventional Procedures](#), [Medical Technologies](#) and [Diagnostics](#).

**NOTES:**

- Potentially exceptional circumstances may be considered by a patient's ICB where there is evidence of significant health status impairment (e.g. inability to perform activities of daily living) and there is evidence that the intervention sought would improve the individual's health status.
- This policy was developed and recommended by Thames Valley Priorities Committee which was the predecessor of Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee.
- This policy will be reviewed in the light of new evidence or new national guidance, e.g., from NICE.
- BOBFPC clinical policies can be viewed at [Clinical Commissioning Policy Statements & IFRs | BOB ICB](#)

<b>Recommendation made by TVPC</b>	March 2016 January 2021
<b>Date adopted and issued by OCG</b>	June 2016 January 2021
<b>Date of BOB ICB adoption</b>	March 2024 – reformatted and rebadged only